Pharmaceutical - Forest Laboratories

Filter

Current filters:

Forest Laboratories

Popular Filters

1 to 25 of 72 results

Positive Ph III results with Forest Labs’ vilazodone in GAD

24-06-2014

US drugmaker Forest Laboratories has released positive top-line results from three Phase III trials evaluating…

Forest LaboratoriesNeurologicalPharmaceuticalResearchvilazodone

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

Adamas Pharma gets $25 million milestone from Forest Labs

21-05-2014

Adamas Pharmaceuticals says it has received a $25 million milestone payment from Forest Laboratories…

Adamas PharmaceuticalsFinancialForest LaboratoriesMDX-8704NeurologicalPharmaceuticalRegulationUSA

Actavis announces proposed Senior Leadership Team

Actavis announces proposed Senior Leadership Team

14-05-2014

US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead…

ActavisBiosimilarsBoardroomForest LaboratoriesPharmaceuticalUSA

Forest Labs sales top analysts’ forecasts

29-04-2014

US drugmaker Forest Laboratories, currently the subject of a takeover by Actavis, has reported diluted…

FinancialForest LaboratoriesPharmaceutical

Forest Labs to acquire Furiex Pharma in $1.46 billion deal

29-04-2014

US drugmaker Forest Laboratories has entered into a definitive agreement to acquire Furiex Pharmaceuticals…

eluxadolineForest LaboratoriesFuriex PharmaceuticalsGastro-intestinalsMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Positive mid-stage results for Forest Labs and Gedeon Richter’s cariprazine in MDD

21-03-2014

US drugmaker Forest Laboratories and Gedeon Richter, Hungary’s largest pharma company, have released…

cariprazineForest LaboratoriesGedeon RichterNeurologicalPharmaceuticalResearch

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Adamas Pharma earns $40 milestone in Forest deal

10-01-2014

California, USA-based Adamas Pharmaceuticals revealed yesterday (January 9) that it has received $40…

Adamas PharmaceuticalsdonepezilFinancialForest LaboratoriesMDX-8704NamendaNeurologicalPharmaceuticalResearch

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

06-01-2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA,…

BrazilColoBreatheForest LaboratoriesLicensingMerck SeronoMoksha8NeurologicalPharmaceuticalRare diseasesRegulationSouth AmericaViibryd

Forest debuts MMD drug Fetzima in US pharmacies

19-12-2013

US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Forest spends $240 million for US rights to Saphris; streamlines operations

02-12-2013

US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

FDA calls for more info from Forest and Gedeon Richter on cariprazine

21-11-2013

The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application…

cariprazineForest LaboratoriesGedeon RichterNeurologicalNorth AmericaPharmaceuticalRegulation

Antibiotic ceftaroline fosamil shows promise for treating MRSA pneumonia

12-09-2013

A drug approved just two years ago for treating bacterial infections may hold promise for treating the…

Antibiotics and Infectious diseasesAstraZenecaceftaroline fosamilForest LaboratoriesPharmaceuticalResearchTeflaroZinforo

Forest Labs names new CEO to replace Howard Solomon

11-09-2013

US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September…

BoardroomFinancialForest LaboratoriesNorth AmericaPharmaceutical

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

1 to 25 of 72 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top